The global Hypersomnia Market is growing from USD 3.82 billion in 2025 to USD 5.98 billion by 2035 at a CAGR of 4.56% — a market whose growth reflects a long-overdue shift in how the medical community, patients, and pharmaceutical companies are approaching excessive daytime sleepiness as a clinically serious, treatable condition rather than a personal failing or lifestyle issue.

Hypersomnia encompasses a group of sleep disorders characterized by excessive daytime sleepiness and prolonged sleep duration that persists despite adequate or extended nighttime sleep. The primary subtypes have distinct clinical profiles: idiopathic hypersomnia — excessive sleepiness without identifiable cause — is the dominant market segment, valued at USD 2.31 billion in 2024, reflecting its prevalence among diagnosed patients. Kleine-Levin syndrome, while rare, is the fastest-growing segment in terms of clinical research and market attention, characterized by recurrent episodes of hypersomnia lasting days to weeks, often accompanied by cognitive and behavioral changes.

The condition's impact on patients is not merely clinical — it is profoundly occupational and social. Patients with severe hypersomnia struggle to maintain employment, drive safely, sustain relationships, and engage in normal daily activities. The adult segment dominates at USD 2.2 billion in 2024, driven by the condition's impact on working-age individuals and the high occupational impairment it creates. Adolescents are the fastest-growing age segment — driven by rising academic pressure, excessive screen time disrupting sleep architecture, and growing recognition among clinicians and school systems that hypersomnia is a medical condition, not academic disengagement.

Pharmacological treatments are the dominant therapeutic approach at USD 1.9 billion in 2024, serving the largest share of treated patients. The key pharmacological agents include modafinil and armodafinil (wakefulness-promoting agents), sodium oxybate (Jazz Pharmaceuticals' Xyrem/Lumryz), and stimulant medications. Jazz Pharmaceuticals has been particularly active in the hypersomnia space — its once-nightly sodium oxybate formulation Lumryz specifically targets the compliance barrier associated with the middle-of-the-night dosing requirement of traditional twice-nightly sodium oxybate, representing meaningful patient-centric innovation.

Wakefulness-promoting agents are the fastest-growing therapeutic sub-segment, driven by the development of next-generation agents with improved efficacy and tolerability profiles. The growing investment in selective histamine H3 receptor antagonists and other novel wake-promoting mechanisms reflects pharmaceutical industry conviction that the current wakefulness agent options have addressable limitations that new drugs can overcome.

Polysomnography remains the dominant diagnostic method at USD 1.8 billion, providing comprehensive overnight sleep architecture assessment that establishes hypersomnia diagnosis and rules out other sleep disorders. The Multiple Sleep Latency Test (MSLT) — measuring how quickly a patient falls asleep across multiple scheduled daytime nap opportunities — is the fastest-growing diagnostic tool, increasingly essential for distinguishing idiopathic hypersomnia from narcolepsy.

North America holds 45% of market share; Europe 30%; Asia-Pacific 20%. Key players include Jazz Pharmaceuticals, Eli Lilly, Avadel Pharmaceuticals, Teva, AstraZeneca, and Takeda. The market's growth to USD 5.98 billion by 2035 is being driven by rising awareness, improved diagnostic clarity, and a pharmaceutical pipeline that is beginning to provide genuinely novel therapeutic options for a patient population that has historically been underserved.

 #Hypersomnia #ExcessiveDaytimeSleepiness #SleepDisorders #IdiopathicHypersomnia #ModafinilMarket #SleepMedicine #HypersomniaMarket